Current Liabilities
Accrued Expenses
Incyte Accrued Expenses decreased by 45.2% to $124.92M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.5%, from $102.82M to $124.92M. Over 5 years (FY 2020 to FY 2025), Accrued Expenses shows an upward trend with a 15.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026Apr 28, 2026
How to read this metric
Significant changes may reflect shifts in operational activity, such as increased R&D project accruals or changes in compensation structures.
Detailed definition
Liabilities for expenses that have been incurred but not yet invoiced or paid by the end of the reporting period. Common...
Peer comparison
Common across all industries; levels are typically proportional to the scale of operations and R&D intensity.
Metric ID:
accrued_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.76M | $105.71M | $108.96M | $83.66M | $93.15M | $106.31M | $138.76M | $84.72M | $111.71M | $124.78M | $153.35M | $89.11M | $113.54M | $150.72M | $188.68M | $102.82M | $129.11M | $168.25M | $228.07M | $124.92M |
| QoQ Change | — | +27.7% | +3.1% | -23.2% | +11.3% | +14.1% | +30.5% | -38.9% | +31.9% | +11.7% | +22.9% | -41.9% | +27.4% | +32.8% | +25.2% | -45.5% | +25.6% | +30.3% | +35.6% | -45.2% |
| YoY Change | — | — | — | — | +12.5% | +0.6% | +27.3% | +1.3% | +19.9% | +17.4% | +10.5% | +5.2% | +1.6% | +20.8% | +23.0% | +15.4% | +13.7% | +11.6% | +20.9% | +21.5% |
Range$82.76M – $228.07M
CAGR+9.1%
Avg YoY Growth+14.0%
Median YoY Growth+14.6%
Product Breakdown
| Segment | Q4 '25 |
|---|---|
| Axatilimab - Commercialization Activities | $27.6M |
| Axatilimab - Development Activities | $2.4M |
| Total | $228.07M |
Accrued Expenses at Other Companies
Frequently Asked Questions
- What is Incyte's accrued expenses?
- Incyte (INCY) reported accrued expenses of $124.92M in Q1 2026.
- How has Incyte's accrued expenses changed year-over-year?
- Incyte's accrued expenses increased by 21.5% year-over-year, from $102.82M to $124.92M.
- What is the long-term trend for Incyte's accrued expenses?
- Over 5 years (2020 to 2025), Incyte's accrued expenses has grown at a 15.0% compound annual growth rate (CAGR), from $113.34M to $228.07M.
- What does accrued expenses mean?
- Expenses the company has incurred but has not yet paid for.